[Expert consensus on the use of pegylated recombinant human granulocyte colony-stimulating factor in the treatment of hematologic malignancies (2026 edition)].

Neutropenia is one of the most common hematologic toxicities during the treatment of hematologic malignancies. It can lead to delays in subsequent treatments, dose reduction of chemotherapeutic agents, or even treatment discontinuation. Furthermore,…

Preview only. Read the full abstract at the source